GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Alkem Laboratories Ltd

Alkem Laboratories Board Approves Q2 FY27 Consolidated Financial Results

RESULTS ● No Immediate Change MEDIUM RISK
📅 Filed on BSE: 12 Nov 2026, 01:50 PM IST  ·  BSE ID: 965f2a18-4c23-4720-83bd-0ba3fd043f5a
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board has approved and released its financial report for the July-September 2026 period.
🤖 AI Summary
  • Alkem Laboratories' Board of Directors approved consolidated unaudited financial results for Q2 FY27 on November 12, 2026.
  • The financial results cover the quarter and half year period ended September 30, 2026.
  • The board meeting, previously intimated on November 4, 2026, concluded at 1:40 p.m.
  • Consolidated results include 5 subsidiaries reviewed by other auditors, reflecting Rs. 6,013.9 million revenue for the quarter.
  • Consolidated results also include 28 subsidiaries not reviewed by auditors, with Rs. 1,661.7 million revenue for the quarter.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Total assets of 5 subsidiaries reviewed by other auditors (as at September 30, 2026)
Rs. 15,803.8 million
Total revenues of 5 subsidiaries reviewed by other auditors (Q2 FY27)
Rs. 6,013.9 million
Total net profit after tax of 5 subsidiaries reviewed by other auditors (Q2 FY27)
Rs. 401.6 million
Total assets of 28 subsidiaries not reviewed by auditors (as at September 30, 2026)
Rs. 11,605.5 million
Total revenue of 28 subsidiaries not reviewed by auditors (Q2 FY27)
Rs. 1,661.7 million
Total net loss after tax of 28 subsidiaries not reviewed by auditors (Q2 FY27)
Rs. 284.2 million
Group's share of loss after tax of one associate (Q2 FY27)
Rs. 6.1 million
🏢 How This Affects the Company
⚠️
Risk Impact
The consolidated financial results include interim information from twenty-eight subsidiaries and one associate that have not been reviewed by their auditors, representing Rs. 1,661.7 million in total revenue for the quarter ended September 30, 2026.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this board meeting outcome.
👤
Who Is Affected
Shareholders are affected by the company's financial disclosures, as these results provide an update on the company's performance for the quarter and half year ended September 30, 2026.
🔍
Management Signal
The approval and disclosure of the unaudited financial results indicate management's adherence to regulatory compliance and commitment to periodic financial reporting.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Review detailed Q2 FY27 financial results for revenue and profit figures.
Monitor subsequent auditor reports for subsidiaries not reviewed currently.
Observe investor calls or presentations for management commentary on Q2 FY27.
MEDIUM RISK The consolidated results include unreviewed financial information from a significant number of subsidiaries and an associate.
💡 Investor Takeaway
Alkem Laboratories' Board approved consolidated unaudited financial results for Q2 FY27 (quarter ended September 30, 2026). The results incorporate data from five subsidiaries reviewed by other auditors, contributing Rs. 6,013.9 million revenue, and twenty-eight unreviewed subsidiaries, contributing Rs. 1,661.7 million revenue for the quarter.
⚖️ Strengths & Concerns

⚠️ Concerns

  • Consolidated results incorporate interim financial information of 28 subsidiaries (Rs. 1,661.7 million revenue, Q2 FY27) not reviewed by auditors.
  • Group's share of loss after tax from one associate (Rs. 6.1 million, Q2 FY27) is based on unreviewed interim financial information.
📅 Company Track Record
Alkem Laboratories reported Q1 FY27 consolidated revenue grew 10.95% to ₹37,401.5 Million, with net profit down 21.7%. The company achieved record FY26 EBITDA of ₹30,052 million and 14.6% Q4 FY26 revenue growth.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was the date of Alkem Laboratories' board meeting for Q2 FY27 results?
Alkem Laboratories' Board of Directors meeting to approve Q2 FY27 financial results was held on November 12, 2026.
Which financial period do these approved results for Alkem Laboratories cover?
The approved financial results for Alkem Laboratories cover the quarter and half year ended September 30, 2026 (Q2 FY27).
What revenue did the subsidiaries reviewed by other auditors contribute to Alkem Laboratories' consolidated results for Q2 FY27?
Five subsidiaries reviewed by other auditors contributed total revenues of Rs. 6,013.9 million for the quarter ended September 30, 2026, to Alkem Laboratories' consolidated results.
What revenue did the subsidiaries not reviewed by auditors contribute to Alkem Laboratories' consolidated results for Q2 FY27?
Twenty-eight subsidiaries, whose financial information was not reviewed by auditors, contributed total revenue of Rs. 1,661.7 million for the quarter ended September 30, 2026, to Alkem Laboratories' consolidated results.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.